Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
[ad_1]
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Global biopharma R&D productivity rebounded in 2023 with higher composite success rates enabled by industry-wide and regulator adoption of data and technology driven innovation, including novel trial design, optimized biomarker use, and digital and decentralized trial methodologies. This rebound occurred while clinical trial starts and funding returned to pre-pandemic levels, according to the new report, “Global Trends in R&D 2024: Activity
[ad_2]
